HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

NPC 12626

N-methyl-D-aspartate receptor antagonist; structure given in first source; NPC 17742, the (2R,4R,5S)-isomer, is the most potent isomer in the mixture NPC 12626
Also Known As:
2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid; GPI 3000; GPI-3000; NPC 17742; NPC-12626; NPC-17742; Cyclohexanepropanoic acid, alpha-amino-2-(2-phosphonoethyl)-
Networked: 6 relevant articles (3 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1. Brain Ischemia (Cerebral Ischemia)
2. Ischemia
07/01/1989 - "Furthermore, low doses (25 mg/kg) of NPC 12626 given i.v. were effective in preventing damage to the CA1 region of hippocampus in the gerbil model of global ischemia. "
11/01/1994 - "Because NPC 17742 afforded protection when administered at the end of ischemia and during reperfusion, NMDA receptor activation during reperfusion may contribute to the progression of injury in ischemic border regions."
11/01/1994 - "Experimental cats were treated with NPC 17742 at a dose of 5 mg/kg IV from 45 minutes of ischemia to 15 minutes of reperfusion and 2.5 mg/kg per hour for 4 hours of reperfusion (NPC-5; n = 7) or 50 mg/kg from 45 minutes of ischemia to 15 minutes of reperfusion and 25 mg/kg per hour for 4 hours of reperfusion (NPC-50; n = 5). "
11/01/1994 - "We tested the hypothesis that administration of the competitive N-methyl-D-aspartate (NMDA) receptor antagonist NPC 17742 (2R,4R,5S-[2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid]) during transient focal ischemia affects early postischemic brain injury. "
06/01/1997 - "We tested the hypothesis that the administration of the competitive N-methyl-D-aspartate (NMDA) receptor antagonist 2R,4R,5S-(2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid) (NPC 17742) or cis-4-(phosphonomethyl) piperidine-2-carboxylic acid (CGS 19755) or the noncompetitive NMDA receptor antagonist dizocilpine (MK-801), at the appropriate doses, would all have efficacy in decreasing early postischemic brain injury in a feline model of transient focal ischemia. "
3. Acidosis
4. Brain Injuries (Brain Injury)
5. Shock

Related Drugs and Biologics

1. N-Methylaspartate (NMDA)
2. Iron
3. Deferoxamine (Desferal)
4. Dizocilpine Maleate (Dizocilpine)
5. Pentylenetetrazole (Metrazol)
6. Buspirone (Buspar)
7. selfotel
8. 3- (2- carboxypiperazin- 4- yl)propyl- 1- phosphonic acid (CPP)
9. tranilast (N 5')